Recherche
Résultats 1-4 de 4
-
Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study
The Lancet. Oncology, 2015, 16, 704-715Article dans une revue scientifique -
Anti-CD22 and anti-CD79B antibody drug conjugates are active in different molecular diffuse large B-cell lymphoma subtypes
Leukemia, 2015, 29, 1578-1586Article dans une revue scientifique -
Cytokine release in patients with CLL treated with obinutuzumab and possible relationship with infusion-related reactions
Blood, 12-2015, 126, 2646-2649Article dans une revue scientifique -
International Prognostic Index, Type of Transplant and Response to Rituximab Are Key Parameters to Tailor Treatment in Adults With CD20-Positive B Cell PTLD: Clues From the PTLD-1 Trial
American journal of transplantation, 2015, 15, 1091-1100Article dans une revue scientifique